{"brief_title": "A Study of CI-1012 in HIV-Infected Patients", "brief_summary": "The purpose of this study is to see if it is safe and effective to give CI-1012 to HIV-infected patients who do not have any symptoms of the disease. This study also examines how the body handles CI-1012.", "detailed_description": "Patients receive 2 weeks of oral CI-1012 therapy in this open-label study, with 8 patients entered at each dose level studied.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "CI-1012", "criteria": "Inclusion Criteria Patients must have: - Serologic evidence of infection with HIV-1. - CD4+ cell count >= 200 cells/mm3. - HIV-1 RNA >= 10,000 copies/ml. Exclusion Criteria Co-existing Condition: Patients with the following conditions are excluded: Viral, fungal, or bacterial infection requiring therapy other than topical medications. Concurrent Medication: Excluded: - Prophylactic systematic antibacterial, antifungal or antiviral agents. - Antiretroviral therapy. NOTE: - Patient must be willing to remain off antiretroviral therapy for 1 week after completing study medication. Prior Medication: Excluded: - Experimental therapy for >= 4 weeks prior to initiation of study medication. - Antiretroviral treatment for 3 weeks prior to initiation of study medication. - Systemic steroids or anticancer agents for 4 weeks prior to initiation of study medication.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "60 Years", "healthy_volunteers": "No", "id": "NCT00002196.xml"}